Trevor Allred
Stock Analyst at Oppenheimer
(4.89)
# 268
Out of 4,630 analysts
44
Total ratings
90.3%
Success rate
86.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $157.77 | +33.11% | 9 | Aug 5, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $108.92 | - | 7 | May 11, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $84.48 | - | 10 | May 11, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $27 → $14 | $16.93 | -19.26% | 2 | Mar 5, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $20.51 | +70.65% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $250 → $275 | $293.15 | -6.19% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintained: Buy | $38 → $80 | $67.82 | +17.96% | 4 | Nov 7, 2025 |
Palvella Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $210
Current: $157.77
Upside: +33.11%
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $108.92
Upside: -
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $84.48
Upside: -
Theravance Biopharma
Mar 5, 2026
Downgraded: Hold
Price Target: $27 → $14
Current: $16.93
Upside: -19.26%
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $20.51
Upside: +70.65%
Ligand Pharmaceuticals
Nov 7, 2025
Maintained: Buy
Price Target: $250 → $275
Current: $293.15
Upside: -6.19%
MBX Biosciences
Nov 7, 2025
Maintained: Buy
Price Target: $38 → $80
Current: $67.82
Upside: +17.96%